Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05533775 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
A Phase 1 study of Mature B-Cell Non-Hodgkin Lymphoma, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
- 20
- Study locations
NCT05533775: Recruiting Phase 1 study of Mature B-Cell Non-Hodgkin Lymphoma, sponsored by Hoffmann-La Roche.
NCT05533775 is a Phase 1 study of Mature B-Cell Non-Hodgkin Lymphoma that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 65 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05533775, a Phase 1 study of Mature B-Cell Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of glofitamab, as monotherapy and in combination with a standard chemoimmunotherapy regimen: rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in pediatric and young adult participants with relapsed and refractory (R/R) mature B-cell non-Hodgkin lymphoma (B-NHL).
Conditions Studied
Interventions
- DRUG Obinutuzumab
- DRUG Glofitamab
- DRUG Carboplatin
- DRUG Rituximab
- DRUG Ifosfamide
Study Locations (20)
Other
- Sun Yet-sen University Cancer Center - Guangzhou
- Fakultni nemocnice v Motole;Klinika detske hematologie a onkologie - Prague
- Rigshospitalet - København Ø
- Hôpital Pellegrin - Bordeaux
- Gustave Roussy - Villejuif
- Universitaetsklinikum Muenster - Münster
California
- UCSF Benioff Children's Hospital Oakland - Oakland
- Kaiser Permanente Oakland Medical Center - Oakland
- Kaiser Permanente - Roseville - Roseville
- Kaiser Permanente - Santa Clara - Santa Clara
Alabama
- Children's Hospital of Alabama - Birmingham
Maryland
- Johns Hopkins University - Baltimore
Massachusetts
- Dana-Farber Cancer Institute - Boston
Missouri
- Childrens Mercy Hosp & Clinics - Kansas City
New York
- MSKCC - New York
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2022-11-16 |
| Est. Completion | 2032-11-30 |
| Phase | Phase 1 |
What NCT05533775 shows while recruiting
NCT05533775 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 1 condition, with Mature B-Cell Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Obinutuzumab is the first listed.
NCT05533775 names 20 study sites across 12 states, led by Other, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT05533775 about?
NCT05533775 is a clinical study titled "A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma". The purpose of this study is to evaluate the safety and efficacy of glofitamab, as monotherapy and in combination with a standard chemoimmunotherapy regimen: rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in pediatric and young adult participants with relapsed and refractory (R/R) mature ...
What is the current status of trial NCT05533775?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2022-11-16. Estimated completion is 2032-11-30.
What conditions does trial NCT05533775 study?
This clinical trial studies the following conditions: Mature B-Cell Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT05533775?
The interventions under investigation include: Obinutuzumab (DRUG), Glofitamab (DRUG), Carboplatin (DRUG), Rituximab (DRUG), Ifosfamide (DRUG).
Who is sponsoring clinical trial NCT05533775?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05533775 being conducted?
This trial has 20 study locations across Alabama, California, Maryland, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05533775's enrollment target sits among peer trials
65 799th of 2000 higher than 1,193 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI